Expect a negative stock reaction as the market prices in the loss of a major pipeline asset. Monitor for analyst downgrades of Novartis's net present value (NPV) for pelacarsen and any potential write-downs related to the Ionis license. The full data presentation at an upcoming medical congress may provide further detail on subgroup analyses.
NVS drugs
NVS drug pipeline →- ● Cosentyx 4/10 Approved (marketed); additional Phase 3 programs completed/terminated
- ● del-zota 4/10 Filed/PDUFA (BLA under Priority Review, Accelerated Approval pathway)
- ● Fabhalta 4/10 Approved (marketed); Phase 3 readout pending in aHUS
- ◆ ianalumab 4/10 Phase 3
- ● Scemblix 4/10 Approved (pivotal Phase 3 ASCEMBL completed; additional Phase 2/3 studies mostly completed or terminated)
- 16 more · All NVS drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 8 $137.70entry
- T+1 · 2mo ago −0.16%α +0.30% · $137.48
- T+5 · 2mo ago +0.67%α +1.79% · $138.62
- T+20 · 6w ago +2.24%α +0.53% · $140.79
- T+49 · todayOpen
- T+60 · in 16d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen, an investigational antisense oligonucleotide targeting elevated lipoprotein(a), did not meet the primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established CVD. Despite achieving lower Lp(a) levels, the drug failed to translate biomarker reduction into clinical benefit, eliminating a major pipeline opportunity in a large unmet cardiovascular market.
Key Facts
- Pelacarsen Phase III Lp(a)HORIZON trial (NCT04023552) did not meet its primary composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, and urgent coronary revascularization requiring hospitalization.
- Trial enrolled 8,323 patients with elevated Lp(a) (≥70 mg/dL) and established CVD; lower Lp(a) levels were achieved but did not reduce cardiovascular risk.
- Novartis obtained global rights to pelacarsen under a license and collaboration agreement with Ionis Pharmaceuticals.
- Elevated Lp(a) affects approximately 20% of the global population with no approved targeted treatment.
Financial Impact
Failure of a high-profile Phase III cardiovascular outcomes trial eliminates a significant future revenue opportunity for Novartis; no specific financial figures provided in the filing.
Risk Factors
- Potential impairment of intangible assets related to the pelacarsen license from Ionis Pharmaceuticals.
- Loss of future revenue stream from a drug targeting a large unmet cardiovascular need.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005896 |
| Document: 0001171843-26-005896-index-headers.html | 0001171843-26-005896 |
| Document: 0001171843-26-005896-index.html | 0001171843-26-005896 |
| Document: 0001171843-26-005896.txt | 0001171843-26-005896 |
Track record
16 reports on NVS
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +6.86% at T+60 after the Jul 1, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 12, 20263d ago 6-K Neutral 3/10 Entry $160.98 Now $160.20 −0.48% due Nov 16
- Nov 10, 20266d ago PTAB Trial Neutral 3/10 Entry $163.26 to $160.32 Now $160.20 −1.87% ▼ −1.80% −3.12% vs SPY
- Oct 28, 202619d ago 144 Neutral 2/10 Entry $156.08 to $161.10 Now $160.20 +2.64% ▲ +3.22% +3.60% vs SPY
- Oct 27, 202620d ago 6-K Mixed 6/10 Entry $156.86 to $156.08 Now $160.20 +2.13% ▼ −0.50% −0.84% vs SPY
- Oct 15, 20264w ago Court Ruling Neutral 2/10 Entry $150.62 to $150.20 Now $160.20 +6.36% ▼ −0.28% −0.70% vs SPY
- Oct 13, 20264w ago Court Ruling Bearish 5/10 Entry $146.88 to $150.38 Now $160.20 −9.07% ▼ −2.38% −2.10% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $141.28 to $142.71 Now $160.20 +13.39% ▲ +1.01% +1.73% vs SPY
- Sep 4, 202610w ago 6-K Bearish 6/10 Viewing Entry $137.70 to $137.48 Now $160.20 −16.34% ▲ +0.16% −0.30% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $161.25 to $162.46 Now $160.20 −0.65% ▲ +0.75% +0.31% vs SPY
- Aug 4, 202614w ago Court Ruling Neutral 2/10 Entry $154.44 to $154.21 Now $160.20 +3.73% ▼ −0.15% +0.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers